These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 7851482

  • 41. [Changes in systemic fibrinolysis and blood coagulation parameters in local thrombolysis with tissue plasminogen activator (rt-PA)].
    Klein P, Roth FJ, Rieger H, Popov-Cenic S.
    Vasa; 1992; 21(3):249-52. PubMed ID: 1529628
    [Abstract] [Full Text] [Related]

  • 42. The usefulness of systemic administration of recombinant human tissue-type plasminogen activator in femoral arterial thrombolysis of rabbits.
    Mino T, Suzuki J, Hayashi H.
    Jpn J Pharmacol; 1989 Aug; 50(4):429-33. PubMed ID: 2476578
    [Abstract] [Full Text] [Related]

  • 43. Antiplatelet effect of Z-335, a new orally active and long-lasting thromboxane receptor antagonist.
    Tanaka T, Fukuta Y, Higashino R, Sato R, Nomura Y, Fukuda Y, Ito S, Takei M, Kurimoto T, Tamaki H.
    Eur J Pharmacol; 1998 Sep 11; 357(1):53-60. PubMed ID: 9788773
    [Abstract] [Full Text] [Related]

  • 44. Low molecular weight heparin (Fragmin) prevents early reocclusion following femoral artery thrombolysis with rt-PA in rabbits.
    Kornowski R, Glikson M, Hasdai D, Chernine A, Ohad D, Battler A.
    Eur Heart J; 1994 Apr 11; 15(4):541-6. PubMed ID: 8070483
    [Abstract] [Full Text] [Related]

  • 45. Effect of combination of a tissue-type plasminogen activator and an endothelin receptor antagonist, FR139317, in the rat cerebral infarction model.
    Umemura K, Ishiye M, Kosuge K, Nakashima M.
    Eur J Pharmacol; 1995 Feb 24; 275(1):17-21. PubMed ID: 7774658
    [Abstract] [Full Text] [Related]

  • 46. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
    Golino P, Ashton JH, Glas-Greenwalt P, McNatt J, Buja LM, Willerson JT.
    Circulation; 1988 Mar 24; 77(3):678-84. PubMed ID: 3124975
    [Abstract] [Full Text] [Related]

  • 47. Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding.
    Kawano KI, Hokamura K, Kondo K, Ikeda Y, Suzuki Y, Umemura K.
    Eur J Pharmacol; 2001 Apr 13; 417(3):217-22. PubMed ID: 11334853
    [Abstract] [Full Text] [Related]

  • 48. [Low-dose thrombolysis using rt-Pa in extensive peripheral vascular occlusion].
    Jung EM, Lutz R, Rupp N.
    Rofo; 2000 Dec 13; 172(12):1028-34. PubMed ID: 11199431
    [Abstract] [Full Text] [Related]

  • 49. Conjunctive effects of the 5HT(2) receptor antagonist, sarpogrelate, on thrombolysis with modified tissue plasminogen activator in different laser-induced thrombosis models.
    Yamashita T, Kitamori K, Hashimoto M, Watanabe S, Giddings JC, Yamamoto J.
    Haemostasis; 2000 Dec 13; 30(6):321-32. PubMed ID: 11357001
    [Abstract] [Full Text] [Related]

  • 50. Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin.
    White BP, Sullivan AT, Lumley P.
    Thromb Haemost; 1994 Mar 13; 71(3):366-74. PubMed ID: 8029802
    [Abstract] [Full Text] [Related]

  • 51. Transcatheter thrombolysis with high-dose bolus tissue plasminogen activator in iatrogenic arterial occlusion after femoral arterial catheterization.
    Tsetis DK, Kochiadakis GE, Hatzidakis AA, Skalidis EI, Chryssou EG, Tritou IN, Vardas PE, Gourtsoyiannis NC.
    Cardiovasc Intervent Radiol; 2002 Mar 13; 25(1):36-41. PubMed ID: 11907772
    [Abstract] [Full Text] [Related]

  • 52. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY, Nichols WW, Mattsson C, Teger-Nilson AC, Wallin R, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1995 Dec 13; 30(6):866-74. PubMed ID: 8746200
    [Abstract] [Full Text] [Related]

  • 53. Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis.
    Shebuski RJ, Storer BL, Fujita T.
    Thromb Res; 1988 Dec 01; 52(5):381-92. PubMed ID: 3146820
    [Abstract] [Full Text] [Related]

  • 54. A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs.
    Schneider J, Hauser R, Hennies HH, Korioth J, Steffens G, Wnendt S.
    Thromb Haemost; 1997 Mar 01; 77(3):535-9. PubMed ID: 9066007
    [Abstract] [Full Text] [Related]

  • 55. Effect of dietary docosahexaenoic acid in the rat middle cerebral artery thrombosis model.
    Umemura K, Toshima Y, Asai F, Nakashima M.
    Thromb Res; 1995 Jun 01; 78(5):379-87. PubMed ID: 7660354
    [Abstract] [Full Text] [Related]

  • 56. Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis model.
    Spriggs D, Gold HK, Hashimoto Y, Van Houtte E, Vermylen J, Collen D.
    Thromb Haemost; 1989 Feb 28; 61(1):93-6. PubMed ID: 2501892
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Effect of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on tPA-induced thrombolysis in a rabbit model of femoral arterial thrombosis.
    Fujita T, Hasan S, Storer BL, Shebuski RJ.
    Fundam Clin Pharmacol; 1989 Feb 28; 3(6):643-53. PubMed ID: 2533138
    [Abstract] [Full Text] [Related]

  • 59. L-arginine improves endothelial vasoreactivity and reduces thrombogenicity after thrombolysis in experimental deep venous thrombosis.
    Lin PH, Johnson CK, Pullium JK, Bush RL, Conklin BS, Chen C, Lumsden AB.
    J Vasc Surg; 2003 Dec 28; 38(6):1396-403. PubMed ID: 14681647
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.